{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:08:45Z","timestamp":1790291325071,"version":"4.1.0"},"reference-count":43,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["etj.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Thyroid eye disease (TED) is an immune-mediated disorder of the eye. Intravenous glucocorticoid (GC) is the first-line treatment for patients with active moderate-to-severe TED. However, the response rate is between 50% and 80%. There are still no simple and reliable markers of responsiveness to GC therapy. We aimed to explore the possible role of miR-146a and miR-21 as predictors of responsiveness to GC treatment in TED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We carried out a prospective longitudinal study on 30 consecutive adult patients with active moderate-to-severe TED and eligible for GC therapy. All patients received the standard GC treatment with methylprednisolone i.v. In cases of progressive worsening of Gorman Score for diplopia or with duction restriction &lt;30\u00b0 in at least two consecutive controls, patients also underwent orbital radiotherapy. Response to GC treatment was defined as a decrease of two or more points in the clinical activity score (CAS) or CAS &lt;4\/10 at 24 weeks. Circulating miRNAs were extracted from patients\u2019 serum and quantified by real-time PCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-three (77%) patients responded to GC. Thyroid surgery, higher CAS, greater proptosis and higher pre-treatment circulating levels of miR-146a emerged as predictive factors of responsiveness to GC. A ROC analysis revealed that miR-146a could predict responsiveness to GC with a positive predictive value of 100%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first study investigating the role of pre-treatment circulating miR-21 and miR-146a to predict responsiveness to GC in TED. miR-146a emerged as a simple, objective, new marker of GC sensitivity that could be used to avoid ineffective administration of GC therapy to TED patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-23-0083","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T06:15:18Z","timestamp":1692684918000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":12,"title":["Circulating miR-146a predicts glucocorticoid response in thyroid eye disease"],"prefix":"10.1530","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-4339","authenticated-orcid":true,"given":"Jacopo","family":"Manso","sequence":"first","affiliation":[{"name":"Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy"},{"name":"Department of Women\u2019s and Children\u2019s Health, Pediatric Endocrinology Unit, Padua University Hospital, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Censi","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Clausi","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Piva","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Hang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mondin","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Pedron","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susi","family":"Barollo","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loris","family":"Bertazza","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Midena","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Parrozzani","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-8001","authenticated-orcid":true,"given":"Caterina","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), Endocrinology Unit, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"International Journal of Molecular Medicine","first-page":"911","article-title":"CD4+ T cells and the Th1\/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy","volume":"17","author":"Xia","year":"2006","unstructured":"Xia NZhou SLiang YXiao CShen HPan HDeng HWang N & Li QQ. CD4+ T cells and the Th1\/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy. International Journal of Molecular Medicine200617911\u2013916. (https:\/\/doi.org\/10.3892\/ijmm.17.5.911)"},{"key":"bib2","series-title":"European Journal of Endocrinology","first-page":"491","article-title":"Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' orbitopathy experience","volume":"148","author":"Prummel","year":"2003","unstructured":"Prummel MFBakker AWiersinga WMBaldeschi LMourits MPKendall-Taylor PPerros PNeoh CDickinson AJLazarus JH, Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' orbitopathy experience. European Journal of Endocrinology2003148491\u2013495. (https:\/\/doi.org\/10.1530\/eje.0.1480491)"},{"key":"bib3","series-title":"European Journal of Endocrinology","first-page":"273","article-title":"Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","unstructured":"Bartalena LBaldeschi LDickinson AEckstein AKendall-Taylor PMarcocci CMourits MPerros PBoboridis KBoschi A, Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. European Journal of Endocrinology2008158273\u2013285. (https:\/\/doi.org\/10.1530\/EJE-07-0666)"},{"issue":"4S Supplement 1","key":"bib4","series-title":"Ophthalmic Plastic and Reconstructive Surgery","first-page":"S34","article-title":"Grading severity and activity in thyroid eye disease","volume":"34","author":"Dolman","year":"2018","unstructured":"Dolman PJ. Grading severity and activity in thyroid eye disease. Ophthalmic Plastic and Reconstructive Surgery201834(4S Supplement 1) S34\u2013S40. (https:\/\/doi.org\/10.1097\/IOP.0000000000001150)"},{"key":"bib5","series-title":"Clinical Science","first-page":"177","article-title":"Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy","volume":"5","author":"Rundle","year":"1945","unstructured":"Rundle FF & Wilson CW. Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy. Clinical Science19455177\u2013194."},{"key":"bib6","series-title":"American Journal of Ophthalmology","first-page":"725","article-title":"Modification of the classification of the eye changes of Graves' disease","volume":"83","author":"Werner","year":"1977","unstructured":"Werner SC. Modification of the classification of the eye changes of Graves' disease. American Journal of Ophthalmology197783725\u2013727. (https:\/\/doi.org\/10.1016\/0002-9394(7790140-4)"},{"key":"bib7","series-title":"European Journal of Endocrinology","first-page":"G43","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","unstructured":"Bartalena LKahaly GJBaldeschi LDayan CMEckstein AMarcocci CMarino MVaidya BWiersinga WM & European Group on Graves' Orbitopathy (EUGOGO). The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. European Journal of Endocrinology2021185G43\u2013G67. (https:\/\/doi.org\/10.1530\/EJE-21-0479)"},{"key":"bib8","series-title":"Ophthalmic Plastic and Reconstructive Surgery","first-page":"319","article-title":"VISA Classification for Graves orbitopathy","volume":"22","author":"Dolman","year":"2006","unstructured":"Dolman PJ & Rootman J. VISA Classification for Graves orbitopathy. Ophthalmic Plastic and Reconstructive Surgery200622319\u2013324. (https:\/\/doi.org\/10.1097\/01.iop.0000235499.34867.85)"},{"key":"bib9","series-title":"British Journal of Ophthalmology","first-page":"639","article-title":"Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","unstructured":"Mourits MPKoornneef LWiersinga WMPrummel MFBerghout A & van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. British Journal of Ophthalmology198973639\u2013644. (https:\/\/doi.org\/10.1136\/bjo.73.8.639)"},{"key":"bib10","series-title":"Clinical Endocrinology","first-page":"391","article-title":"Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee","year":"2001","unstructured":"Terwee CBDekker FWMourits MPGerding MNBaldeschi LKalmann RPrummel MF & Wiersinga WM. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clinical Endocrinology200154391\u2013398. (https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01241.x)"},{"key":"bib11","series-title":"European Thyroid Journal","first-page":"9","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy","volume":"5","author":"Bartalena","year":"2016","unstructured":"Bartalena LBaldeschi LBoboridis KEckstein AKahaly GJMarcocci CPerros PSalvi MWiersinga WM & European Group on Graves' Orbitopathy (EUGOGO). The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy. European Thyroid Journal201659\u201326. (https:\/\/doi.org\/10.1159\/000443828)"},{"key":"bib12","series-title":"Leukemia","first-page":"404","article-title":"MicroRNAs in inflammation and immune responses","volume":"26","author":"Contreras","year":"2012","unstructured":"Contreras J & Rao DS. MicroRNAs in inflammation and immune responses. Leukemia201226404\u2013413. (https:\/\/doi.org\/10.1038\/leu.2011.356)"},{"key":"bib13","series-title":"Scientific Reports","first-page":"8386","article-title":"Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves' disease and orbitopathy","volume":"8","author":"Zhang","year":"2018","unstructured":"Zhang LMasetti GColucci GSalvi MCovelli DEckstein AKaiser UDraman MSMuller ILudgate M, Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves' disease and orbitopathy. Scientific Reports201888386. (https:\/\/doi.org\/10.1038\/s41598-018-26700-1)"},{"key":"bib14","series-title":"PLoS One","first-page":"e0221077","article-title":"MicroRNA-27 inhibits adipogenic differentiation in orbital fibroblasts from patients with Graves' orbitopathy","volume":"14","author":"Jang","year":"2019","unstructured":"Jang SYChae MKLee JHLee EJ & Yoon JS. MicroRNA-27 inhibits adipogenic differentiation in orbital fibroblasts from patients with Graves' orbitopathy. PLoS One201914e0221077. (https:\/\/doi.org\/10.1371\/journal.pone.0221077)"},{"key":"bib15","series-title":"Molecular Vision","first-page":"324","article-title":"miRNA-21 promotes fibrosis in orbital fibroblasts from thyroid-associated ophthalmopathy","volume":"21","author":"Tong","year":"2015","unstructured":"Tong BDXiao MYZeng JX & Xiong W. miRNA-21 promotes fibrosis in orbital fibroblasts from thyroid-associated ophthalmopathy. Molecular Vision201521324\u2013334."},{"key":"bib16","series-title":"British Journal of Ophthalmology","first-page":"407","article-title":"Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves' orbitopathy","volume":"102","author":"Jang","year":"2018","unstructured":"Jang SYPark SJChae MKLee JHLee EJ & Yoon JS. Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves' orbitopathy. British Journal of Ophthalmology2018102407\u2013414. (https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310723)"},{"key":"bib17","series-title":"Medical Science Monitor","first-page":"639","article-title":"Increased microRNA-155 and decreased microRNA-146a may promote ocular inflammation and proliferation in Graves' ophthalmopathy","volume":"20","author":"Li","year":"2014","unstructured":"Li KDu YJiang BL & He JF. Increased microRNA-155 and decreased microRNA-146a may promote ocular inflammation and proliferation in Graves' ophthalmopathy. Medical Science Monitor201420639\u2013643. (https:\/\/doi.org\/10.12659\/MSM.890686)"},{"key":"bib18","series-title":"European Review for Medical and Pharmacological Sciences","first-page":"1803","article-title":"Decreased microRNA-146a in CD4+T cells promote ocular inflammation in thyroid-associated ophthalmopathy by targeting NUMB","volume":"21","author":"Hu","year":"2017","unstructured":"Hu ZJHe JFLi KJChen J & Xie XR. Decreased microRNA-146a in CD4+T cells promote ocular inflammation in thyroid-associated ophthalmopathy by targeting NUMB. European Review for Medical and Pharmacological Sciences2017211803\u20131809."},{"key":"bib19","series-title":"Endocrine Journal","first-page":"1087","article-title":"Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy","volume":"61","author":"Wei","year":"2014","unstructured":"Wei HGuan MQin YXie CFu XGao F & Xue Y. Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy. Endocrine Journal2014611087\u20131092. (https:\/\/doi.org\/10.1507\/endocrj.ej14-0246)"},{"key":"bib20","series-title":"Investigative Ophthalmology and Visual Science","first-page":"4027","article-title":"Role of miR-146a in the regulation of inflammation in an in vitro model of Graves' orbitopathy","volume":"57","author":"Jang","year":"2016","unstructured":"Jang SYChae MKLee JHLee EJ & Yoon JS. Role of miR-146a in the regulation of inflammation in an in vitro model of Graves' orbitopathy. Investigative Ophthalmology and Visual Science2016574027\u20134034. (https:\/\/doi.org\/10.1167\/iovs.16-19213)"},{"key":"bib21","series-title":"Clinical Endocrinology","first-page":"145","article-title":"Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy","volume":"62","author":"Terwee","year":"2005","unstructured":"Terwee CBPrummel MFGerding MNKahaly GJDekker FW & Wiersinga WM. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clinical Endocrinology200562145\u2013155. (https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02186.x)"},{"key":"bib22","series-title":"PLoS One","first-page":"e0156044","article-title":"Overexpression of L-type amino acid Transporter 1 (LAT1) and 2 (LAT2): novel markers of neuroendocrine tumors","volume":"11","author":"Barollo","year":"2016","unstructured":"Barollo SBertazza LWatutantrige-Fernando SCensi SCavedon EGaluppini FPennelli GFassina ACitton MRubin B, Overexpression of L-type amino acid Transporter 1 (LAT1) and 2 (LAT2): novel markers of neuroendocrine tumors. PLoS One201611e0156044. (https:\/\/doi.org\/10.1371\/journal.pone.0156044)"},{"key":"bib23","series-title":"International Journal of Molecular Sciences","article-title":"Overexpression of miR-375 and L-type amino acid Transporter 1 in pheochromocytoma and their molecular and functional implications","volume":"23","author":"Manso","year":"2022","unstructured":"Manso JBertazza LBarollo SMondin ACensi SCarducci SFerrara AMBoschin IMZovato SSchiavi F, Overexpression of miR-375 and L-type amino acid Transporter 1 in pheochromocytoma and their molecular and functional implications. International Journal of Molecular Sciences202223. (https:\/\/doi.org\/10.3390\/ijms23052413)"},{"key":"bib24","series-title":"Frontiers in Endocrinology (Lausanne)","first-page":"647369","article-title":"Serum miR-375 for diagnostic and prognostic purposes in medullary thyroid carcinoma","volume":"12","author":"Censi","year":"2021","unstructured":"Censi SBertazza LPiva IManso JBenna CIacobone MMondin APlebani MFaggian DGaluppini F, Serum miR-375 for diagnostic and prognostic purposes in medullary thyroid carcinoma. Frontiers in Endocrinology (Lausanne)202112647369. (https:\/\/doi.org\/10.3389\/fendo.2021.647369)"},{"key":"bib25","series-title":"Thyroid","first-page":"885","article-title":"Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument","volume":"7","author":"Gerding","year":"1997","unstructured":"Gerding MNTerwee CBDekker FWKoornneef LPrummel MF & Wiersinga WM. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid19977885\u2013889. (https:\/\/doi.org\/10.1089\/thy.1997.7.885)"},{"key":"bib26","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"5234","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy","volume":"90","author":"Kahaly","year":"2005","unstructured":"Kahaly GJPitz SHommel G & Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2005905234\u20135240. (https:\/\/doi.org\/10.1210\/jc.2005-0148)"},{"key":"bib27","series-title":"European Thyroid Journal","first-page":"259","article-title":"Graves' orbitopathy: imperfect treatments for a rare disease","volume":"2","author":"Bartalena","year":"2013","unstructured":"Bartalena L. Graves' orbitopathy: imperfect treatments for a rare disease. European Thyroid Journal20132259\u2013269. (https:\/\/doi.org\/10.1159\/000356042)"},{"key":"bib28","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"1999","article-title":"A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy","volume":"99","author":"Zhu","year":"2014","unstructured":"Zhu WYe LShen LJiao QHuang FHan RZhang XWang SWang W & Ning G. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy. Journal of Clinical Endocrinology and Metabolism2014991999\u20132007. (https:\/\/doi.org\/10.1210\/jc.2013-3919)"},{"key":"bib29","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"4454","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","unstructured":"Bartalena LKrassas GEWiersinga WMarcocci CSalvi MDaumerie CBournaud CStahl MSassi LVeronesi G, Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. Journal of Clinical Endocrinology and Metabolism2012974454\u20134463. (https:\/\/doi.org\/10.1210\/jc.2012-2389)"},{"key":"bib30","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"320","article-title":"Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","unstructured":"Zang SPonto KA & Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. Journal of Clinical Endocrinology and Metabolism201196320\u2013332. (https:\/\/doi.org\/10.1210\/jc.2010-1962)"},{"key":"bib31","series-title":"Lancet. Diabetes and Endocrinology","first-page":"287","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","unstructured":"Kahaly GJRiedl MKonig JPitz SPonto KDiana TKampmann EKolbe EEckstein AMoeller LC, Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet. Diabetes and Endocrinology20186287\u2013298. (https:\/\/doi.org\/10.1016\/S2213-8587(1830020-2)"},{"key":"bib32","series-title":"Frontiers in Genetics","first-page":"121","article-title":"Circulating inflamma-miRs in aging and age-related diseases","volume":"4","author":"Olivieri","year":"2013","unstructured":"Olivieri FRippo MRProcopio AD & Fazioli F. Circulating inflamma-miRs in aging and age-related diseases. Frontiers in Genetics20134121. (https:\/\/doi.org\/10.3389\/fgene.2013.00121)"},{"key":"bib33","series-title":"Ageing Research Reviews","first-page":"101374","article-title":"miR-21 and miR-146a: the microRNAs of inflammaging and age-related diseases","volume":"70","author":"Olivieri","year":"2021","unstructured":"Olivieri FPrattichizzo FGiuliani AMatacchione GRippo MRSabbatinelli J & Bonafe M. miR-21 and miR-146a: the microRNAs of inflammaging and age-related diseases. Ageing Research Reviews202170101374. (https:\/\/doi.org\/10.1016\/j.arr.2021.101374)"},{"key":"bib34","series-title":"Journal of Molecular Biology","first-page":"492","article-title":"miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism","volume":"378","author":"Fujita","year":"2008","unstructured":"Fujita SIto TMizutani TMinoguchi SYamamichi NSakurai K & Iba H. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. Journal of Molecular Biology2008378492\u2013504. (https:\/\/doi.org\/10.1016\/j.jmb.2008.03.015)"},{"key":"bib35","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"12481","article-title":"NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses","volume":"103","author":"Taganov","year":"2006","unstructured":"Taganov KDBoldin MPChang KJ & Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences of the United States of America200610312481\u201312486. (https:\/\/doi.org\/10.1073\/pnas.0605298103)"},{"key":"bib36","series-title":"Haematologica","first-page":"1636","article-title":"miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis","volume":"106","author":"Arroyo","year":"2021","unstructured":"Arroyo ABFern\u00e1ndez-P\u00e9rez MPDel Monte A\u00c1guila SM\u00e9ndez RHern\u00e1ndez-Antol\u00edn RGarc\u00eda-Barber Nde Los Reyes-Garc\u00eda AMGonz\u00e1lez-Jim\u00e9nez PArcas MI, miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. Haematologica20211061636\u20131646. (https:\/\/doi.org\/10.3324\/haematol.2019.240226)"},{"key":"bib37","series-title":"Translational Research","first-page":"198","article-title":"Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus","volume":"160","author":"Wang","year":"2012","unstructured":"Wang HPeng WOuyang XLi W & Dai Y. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Translational Research2012160198\u2013206. (https:\/\/doi.org\/10.1016\/j.trsl.2012.04.002)"},{"key":"bib38","series-title":"PLoS One","first-page":"e24604","article-title":"Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis","volume":"6","author":"Waschbisch","year":"2011","unstructured":"Waschbisch AAtiya MLinker RAPotapov SSchwab S & Derfuss T. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One20116e24604. (https:\/\/doi.org\/10.1371\/journal.pone.0024604)"},{"key":"bib39","series-title":"Genetic Testing and Molecular Biomarkers","first-page":"807","article-title":"MicroRNA 146a expression in rheumatoid arthritis: association with tumor necrosis factor-alpha and disease activity","volume":"15","author":"Abou-Zeid","year":"2011","unstructured":"Abou-Zeid ASaad M & Soliman E. MicroRNA 146a expression in rheumatoid arthritis: association with tumor necrosis factor-alpha and disease activity. Genetic Testing and Molecular Biomarkers201115807\u2013812. (https:\/\/doi.org\/10.1089\/gtmb.2011.0026)"},{"key":"bib40","series-title":"New England Journal of Medicine","first-page":"341","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","unstructured":"Douglas RSKahaly GJPatel ASile SThompson EHZPerdok RFleming JCFowler BTMarcocci CMarino M, Teprotumumab for the treatment of active thyroid eye disease. New England Journal of Medicine2020382341\u2013352. (https:\/\/doi.org\/10.1056\/NEJMoa1910434)"},{"key":"bib41","series-title":"European Journal of Endocrinology","first-page":"55","article-title":"The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor","volume":"170","author":"Vannucchi","year":"2014","unstructured":"Vannucchi GCovelli DCampi IOrigo DCurr\u00f2 NCirello VDazzi DBeck-Peccoz P & Salvi M. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. European Journal of Endocrinology201417055\u201361. (https:\/\/doi.org\/10.1530\/EJE-13-0611)"},{"key":"bib42","series-title":"Endocrinologia y Nutricion","first-page":"188","article-title":"Thyroid orbitopathy, an overview with special attention to the role of radiotherapy","volume":"62","author":"Vilar-Gonzalez","year":"2015","unstructured":"Vilar-Gonzalez SLamas-Oliveira CFagundez-Vargas MANunez-Quintanilla ATPerez-Rozos AMerayo-Lloves JEscobar-Barranco JJ & Rico-Perez JM. Thyroid orbitopathy, an overview with special attention to the role of radiotherapy. Endocrinologia y Nutricion201562188\u2013199. (https:\/\/doi.org\/10.1016\/j.endonu.2014.12.004)"},{"key":"bib43","series-title":"Thyroid","first-page":"1439","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch","year":"2022","unstructured":"Burch HBPerros PBednarczuk TCooper DSDolman PJLeung AMMombaerts ISalvi M & Stan MN. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid2022321439\u20131470. (https:\/\/doi.org\/10.1089\/thy.2022.0251)"}],"container-title":["European Thyroid Journal"],"original-title":[],"link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/12\/5\/ETJ-23-0083.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/12\/5\/ETJ-23-0083.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/12\/5\/ETJ-23-0083.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:51:48Z","timestamp":1784555508000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/etj\/article\/2893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":43,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/etj-23-0083","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]}}}